|
1
|
Oda K, Uto H, Mawatari S and Ido A:
Clinical features of hepatocellular carcinoma associated with
nonalcoholic fatty liver disease: A review of human studies. Clin J
Gastroenterol. 8:1–9. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Watanabe S, Hashimoto E, Ikejima K, Uto H,
Ono M, Sumida Y, Seike M, Takei Y, Takehara T, Tokushige K, et al:
Evidence-based clinical practice guidelines for nonalcoholic fatty
liver disease/nonalcoholic steatohepatitis. J Gastroenterol.
50:364–377. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chalasani N, Younossi Z, Lavine JE, Diehl
AM, Brunt EM, Cusi K, Charlton M and Sanyal AJ: The diagnosis and
management of non-alcoholic fatty liver disease: Practice guideline
by the American Association for the Study of Liver Diseases,
American College of Gastroenterology and the American
Gastroenterological Association. Hepatology. 55:2005–2023. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Angulo P: Long-term mortality in
nonalcoholic fatty liver disease: Is liver histology of any
prognostic significance? Hepatology. 51:373–375. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Charlton MR, Burns JM, Pedersen RA, Watt
KD, Heimbach JK and Dierkhising RA: Frequency and outcomes of liver
transplantation for nonalcoholic steatohepatitis in the United
States. Gastroenterology. 141:1249–1253. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tilg H and Moschen AR: Evolution of
inflammation in nonalcoholic fatty liver disease: The multiple
parallel hits hypothesis. Hepatology. 52:1836–1846. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Than NN and Newsome PN: A concise review
of non-alcoholic fatty liver disease. Atherosclerosis. 239:192–202.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lewington S, Clarke R, Qizilbash N, Peto R
and Collins R: Prospective Studies Collaboration: Age-specific
relevance of usual blood pressure to vascular mortality: a
meta-analysis of individual data for one million adults in 61
prospective studies. Lancet. 360:1903–1913. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yusuf S, Hawken S, Ounpuu S, Dans T,
Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J and
Lisheng L: INTERHEART Study Investigators: Effect of potentially
modifiable risk factors associated with myocardial infarction in 52
countries (the INTERHEART study): Case-control study. Lancet.
364:937–952. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
O'Donnell MJ, Xavier D, Liu L, Zhang H,
Chin SL, Rao-Melacini P, Rangarajan S, Islam S, Pais P, McQueen MJ,
et al: INTERSTROKE investigators: Risk factors for ischaemic and
intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE
study): A case-control study. Lancet. 376:112–123. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hamabe A, Uto H, Imamura Y, Kusano K,
Mawatari S, Kumagai K, Kure T, Tamai T, Moriuchi A, Sakiyama T, et
al: Impact of cigarette smoking on onset of nonalcoholic fatty
liver disease over a 10-year period. J Gastroenterol. 46:769–778.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Marchesini G, Brizi M, Morselli-Labate AM,
Bianchi G, Bugianesi E, McCullough AJ, Forlani G and Melchionda N:
Association of nonalcoholic fatty liver disease with insulin
resistance. Am J Med. 107:450–455. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Brea A and Puzo J: Non-alcoholic fatty
liver disease and cardiovascular risk. Int J Cardiol.
167:1109–1117. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Donati G, Stagni B, Piscaglia F, Venturoli
N, Morselli-Labate AM, Rasciti L and Bolondi L: Increased
prevalence of fatty liver in arterial hypertensive patients with
normal liver enzymes: Role of insulin resistance. Gut.
53:1020–1023. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Arima S, Uto H, Ibusuki R, Kumamoto R,
Tanoue S, Mawatari S, Oda K, Numata M, Fujita H, Oketani M, et al:
Hypertension exacerbates liver injury and hepatic fibrosis induced
by a choline-deficient L-amino acid-defined diet in rats. Int J Mol
Med. 33:68–76. 2014.PubMed/NCBI
|
|
16
|
Yi B, Titze J, Rykova M, Feuerecker M,
Vassilieva G, Nichiporuk I, Schelling G, Morukov B and Choukèr A:
Effects of dietary salt levels on monocytic cells and immune
responses in healthy human subjects: A longitudinal study. Transl
Res. 166:103–110. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Haukeland JW, Damås JK, Konopski Z, Løberg
EM, Haaland T, Goverud I, Torjesen PA, Birkeland K, Bjøro K and
Aukrust P: Systemic inflammation in nonalcoholic fatty liver
disease is characterized by elevated levels of CCL2. J Hepatol.
44:1167–1174. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wieckowska A, Papouchado BG, Li Z, Lopez
R, Zein NN and Feldstein AE: Increased hepatic and circulating
interleukin-6 levels in human nonalcoholic steatohepatitis. Am J
Gastroenterol. 103:1372–1379. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cintra DE, Pauli JR, Araújo EP, Moraes JC,
de Souza CT, Milanski M, Morari J, Gambero A, Saad MJ and Velloso
LA: Interleukin-10 is a protective factor against diet-induced
insulin resistance in liver. J Hepatol. 48:628–637. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Esposito K, Pontillo A, Giugliano F,
Giugliano G, Marfella R, Nicoletti G and Giugliano D: Association
of low interleukin-10 levels with the metabolic syndrome in obese
women. J Clin Endocrinol Metab. 88:1055–1058. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Braunersreuther V, Viviani GL, Mach F and
Montecucco F: Role of cytokines and chemokines in non-alcoholic
fatty liver disease. World J Gastroenterol. 18:727–735. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hui JM, Hodge A, Farrell GC, Kench JG,
Kriketos A and George J: Beyond insulin resistance in NASH:
TNF-alpha or adiponectin? Hepatology. 40:46–54. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sánchez-Lozada LG, Mu W, Roncal C, Sautin
YY, Abdelmalek M, Reungjui S, Le M, Nakagawa T, Lan HY, Yu X and
Johnson RJ: Comparison of free fructose and glucose to sucrose in
the ability to cause fatty liver. Eur J Nutr. 49:1–9. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Varagic J, Ahmad S, Voncannon JL, Moniwa
N, Simington SW Jr, Brosnihan BK, Gallagher PE, Habibi J, Sowers JR
and Ferrario CM: Nebivolol reduces cardiac angiotensin II,
associated oxidative stress and fibrosis but not arterial pressure
in salt-loaded spontaneously hypertensive rats. J Hypertens.
30:1766–1774. 2012.PubMed/NCBI
|
|
25
|
Jurewicz M, McDermott DH, Sechler JM,
Tinckam K, Takakura A, Carpenter CB, Milford E and Abdi R: Human T
and natural killer cells possess a functional renin-angiotensin
system: Further mechanisms of angiotensin II-induced inflammation.
J Am Soc Nephrol. 18:1093–1102. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
González GE, Rhaleb NE, D'Ambrosio MA,
Nakagawa P, Liu Y, Leung P, Dai X, Yang XP, Peterson EL and
Carretero OA: Deletion of interleukin-6 prevents cardiac
inflammation, fibrosis and dysfunction without affecting blood
pressure in angiotensin II-high salt-induced hypertension. J
Hypertens. 33:144–152. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bassuk SS, Rifai N and Ridker PM:
High-sensitivity C-reactive protein: Clinical importance. Curr
Probl Cardiol. 29:439–493. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ridker PM, Hennekens CH, Buring JE and
Rifai N: C-reactive protein and other markers of inflammation in
the prediction of cardiovascular disease in women. N Engl J Med.
342:836–843. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Nishida H, Horio T, Suzuki Y, Iwashima Y,
Tokudome T, Yoshihara F, Nakamura S and Kawano Y: Interleukin-6 as
an independent predictor of future cardiovascular events in
high-risk Japanese patients: Comparison with C-reactive protein.
Cytokine. 53:342–346. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Rifai N, Joubran R, Yu H, Asmi M and Jouma
M: Inflammatory markers in men with angiographically documented
coronary heart disease. Clin Chem. 45:1967–1973. 1999.PubMed/NCBI
|
|
31
|
Riquelme A, Arrese M, Soza A, Morales A,
Baudrand R, Pérez-Ayuso RM, González R, Alvarez M, Hernández V,
García-Zattera MJ, et al: Non-alcoholic fatty liver disease and its
association with obesity, insulin resistance and increased serum
levels of C-reactive protein in Hispanics. Liver Int. 29:82–88.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Rotter Sopasakis V, Larsson BM, Johansson
A, Holmäng A and Smith U: Short-term infusion of interleukin-6 does
not induce insulin resistance in vivo or impair insulin signalling
in rats. Diabetologia. 47:1879–1887. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Rotter V, Nagaev I and Smith U:
Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1
adipocytes and is, like IL-8 and tumor necrosis factor-alpha,
overexpressed in human fat cells from insulin-resistant subjects. J
Biol Chem. 278:45777–45784. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lagathu C, Bastard JP, Auclair M, Maachi
M, Capeau J and Caron M: Chronic interleukin-6 (IL-6) treatment
increased IL-6 secretion and induced insulin resistance in
adipocyte: Prevention by rosiglitazone. Biochem Biophys Res Commun.
311:372–379. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Klover PJ, Clementi AH and Mooney RA:
Interleukin-6 depletion selectively improves hepatic insulin action
in obesity. Endocrinology. 146:3417–3427. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Klover PJ, Zimmers TA, Koniaris LG and
Mooney RA: Chronic exposure to interleukin-6 causes hepatic insulin
resistance in mice. Diabetes. 52:2784–2789. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Meda C: The impact of cytokines and
chemokines on non-alcoholic fatty liver disease (NAFLD). Biotech
Mol Biol Nanomed. 2:15–16. 2014.
|
|
38
|
Kim HJ, Higashimori T, Park SY, Choi H,
Dong J, Kim YJ, Noh HL, Cho YR, Cline G, Kim YB and Kim JK:
Differential effects of interleukin-6 and −10 on skeletal muscle
and liver insulin action in vivo. Diabetes. 53:1060–1067. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hong EG, Ko HJ, Cho YR, Kim HJ, Ma Z, Yu
TY, Friedline RH, Kurt-Jones E, Finberg R, Fischer MA, et al:
Interleukin-10 prevents diet-induced insulin resistance by
attenuating macrophage and cytokine response in skeletal muscle.
Diabetes. 58:2525–2535. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Guzik TJ, Hoch NE, Brown KA, McCann LA,
Rahman A, Dikalov S, Goronzy J, Weyand C and Harrison DG: Role of
the T cell in the genesis of angiotensin II induced hypertension
and vascular dysfunction. J Exp Med. 204:2449–2460. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Matrougui K, Abd Elmageed Z, Kassan M,
Choi S, Nair D, Gonzalez-Villalobos RA, Chentoufi AA, Kadowitz P,
Belmadani S and Partyka M: Natural regulatory T cells control
coronary arteriolar endothelial dysfunction in hypertensive mice.
Am J Pathol. 178:434–441. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Eller K, Kirsch A, Wolf AM, Sopper S,
Tagwerker A, Stanzl U, Wolf D, Patsch W, Rosenkranz AR and Eller P:
Potential role of regulatory T cells in reversing obesity-linked
insulin resistance and diabetic nephropathy. Diabetes.
60:2954–2962. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ito M, Suzuki J, Tsujioka S, Sasaki M,
Gomori A, Shirakura T, Hirose H, Ito M, Ishihara A, Iwaasa H and
Kanatani A: Longitudinal analysis of murine steatohepatitis model
induced by chronic exposure to high-fat diet. Hepatol Res.
37:50–57. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Obstfeld AE, Sugaru E, Thearle M,
Francisco AM, Gayet C, Ginsberg HN, Ables EV and Ferrante AW Jr:
C-C chemokine receptor 2 (CCR2) regulates the hepatic recruitment
of myeloid cells that promote obesity-induced hepatic steatosis.
Diabetes. 59:916–925. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Kassel KM, Guo GL, Tawfik O and Luyendyk
JP: Monocyte chemoattractant protein-1 deficiency does not affect
steatosis or inflammation in livers of mice fed a
methionine-choline-deficient diet. Lab Invest. 90:1794–1804. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Marra F and Tacke F: Roles for chemokines
in liver disease. Gastroenterology. 147:577–594. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Itagaki H, Shimizu K, Morikawa S, Ogawa K
and Ezaki T: Morphological and functional characterization of
non-alcoholic fatty liver disease induced by a
methionine-choline-deficient diet in C57BL/6 mice. Int J Clin Exp
Pathol. 6:2683–2696. 2013.PubMed/NCBI
|
